Type 2 Diabetes
Conditions
Keywords
Dapagliflozin, Renal function
Brief summary
The aim of the study is to evaluate the benefits, documented in experimental settings, of treatment with Dapagliflozin in subjects with type 2 diabetes in normal clinical practice. The type of study does not involve immediate risks or direct benefits for the subjects taking part in it. The potential benefits for clinicians and healthcare systems are: greater knowledge of diabetic disease and the study of new treatment options. However, the analysis of the data will allow us to better identify which patients benefit most from treatment with Dapagliflozin.
Detailed description
An observational, multicentric, non-interventional, non-profit, single-arm, retrospective prospective study is proposed, aimed at investigating the therapeutic efficacy at 4 months of a treatment with Dapagliflozin® in subjects with type 2 diabetes mellitus belonging to the Lombard centers who joined the study. Patient recruitment will be carried out at the Unit of Endocrine Diseases and Diabetology in the L. Sacco, Fatebenefratelli and Oftalmico e Macedonio Melloni hospitals, directed by Prof. Paolo Fiorina. Upon enrollment, the informed consent signed and dated by the doctor who informed the patient and by the patient himself will be collected as well as the patient's medical and anamnestic data. This study does not foresee that additional diagnostic or monitoring procedures will be implemented on patients outside of normal clinical practice. The duration of the study per patient after enrollment is 6 months. This study involves the collection of retrospective data (review of patient medical records). The collection of retrospective data will be done to study the clinical characteristics of the patients at the time they started Dapagliflozin®. The study aims to compare the results reported in the literature with the efficacy outcomes in real-life; to this end, the main clinical and biometric parameters of adult patients with type 2 diabetes belonging to the centers that have joined the study and have been on therapy with Dapagliflozin® for at least 4 months will be collected. By compiling an online database, the parameters and the respective 4-month variations will be entered anonymously and processed in an aggregate manner in compliance with current regulations and regulatory activities for the conduct of observational retrospective studies. The insertion of the observations will end after 6 months from the authorization.
Interventions
DRUGDapagliflozin 10mg
Treatment of T2D and cardio-renal prevention
Sponsors
University of Milan
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of type II diabetes mellitus, according to ADA indications for at least 3 months * Males or females\> 18 years old * Stable therapy for at least 3 months with oral hypoglycemic agents / insulin * Prescription of Dapagliflozin®, according to normal clinical practice and local indications for the prescription / reimbursement of the drug.
Exclusion criteria
* Mental incapacity, unavailability or language barriers that preclude adequate understanding or cooperation; * Diagnosis of type 1 diabetes mellitus, maturity-onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA), gestational diabetes mellitus, secondary diabetes mellitus or any other hyperglycemic state other than type 2 diabetes (T2D); * Women who are pregnant or breastfeeding, or women planning to become pregnant; * Previous participation in the study. Participation is defined by having given informed consent to the study; * Participation in another clinical study on T2D that includes any clinical intervention or administration of an investigational drug within 3 months prior to enrollment in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variation in glycated hemoglobin (HbA1c) values (% -point) from baseline to 4 months from enrollment | From baseline to 4 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of Body Mass Index (BMI) (kg/m2) | From baseline to 4 months | — |
| Evaluation of hip and waist circumferences (cm) | From baseline to 4 months | — |
| Assessment of the change in fasting glycemic control (mg/dl) | From baseline to 4 months | — |
| Evaluation of glomerular filtration rate (GFR) (ml/min/1.73m2) | From baseline to 4 months | — |
| Evaluation of albuminuria (mg/g creatinine) | From baseline to 4 months | Albuminuria will be assessed as albumin to creatinine ratio (ACR) which is obtained from the ratio of urinary protein concentration to creatinine in spot urine |
| Evaluation of systolic and diastolic blood pressure (mmHg) | From baseline to 4 months | — |
Countries
Italy
Contacts
Primary ContactElio Ippolito, MS
Outcome results
None listed